CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit

Go back to CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
(NASDAQ: CRVO) Delayed: 3.18 -0.16 (4.79%)
Previous Close $3.34    52 Week High $ 
Open $3.26    52 Week Low $ 
Day High $3.36    P/E N/A 
Day Low $3.13    EPS $ 
Volume 309,462